Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) on Friday, plunged -8.00% from the previous trading day, before settling in for the closing price of $1.06. Within the past 52 weeks, LXRX’s price has moved between $1.01 and $3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 186.21% over the past five years. The company achieved an average annual earnings per share of 14.94%. With a float of $310.15 million, this company’s outstanding shares have now reached $361.49 million.
Let’s look at the performance matrix of the company that is accounted for 285 employees. In terms of profitability, gross margin is 87.95%, operating margin of -4044.39%, and the pretax margin is -4116.49%.
Lexicon Pharmaceuticals Inc (LXRX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lexicon Pharmaceuticals Inc is 3.44%, while institutional ownership is 67.30%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000.
Lexicon Pharmaceuticals Inc (LXRX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.2 earnings per share (EPS) for the period topping the consensus outlook (set at -0.23) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.94% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Lexicon Pharmaceuticals Inc (LXRX) is currently performing well based on its current performance indicators. A quick ratio of 7.43 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 62.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) saw its 5-day average volume 3.4 million, a negative change from its year-to-date volume of 3.48 million. As of the previous 9 days, the stock’s Stochastic %D was 12.62%. Additionally, its Average True Range was 0.14.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 0.33%, which indicates a significant decrease from 0.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 201.30% in the past 14 days, which was higher than the 106.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6064, while its 200-day Moving Average is $1.8907. Nevertheless, the first resistance level for the watch stands at $1.0467 in the near term. At $1.1182, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.1564. If the price goes on to break the first support level at $0.9370, it is likely to go to the next support level at $0.8988. Assuming the price breaks the second support level, the third support level stands at $0.8273.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
Market capitalization of the company is 324.33 million based on 246,237K outstanding shares. Right now, sales total 1,200 K and income totals -177,120 K. The company made 1,650 K in profit during its latest quarter, and -53,430 K in sales during its previous quarter.
